with responders, mean values of hemoglobin, rEPO dose, iron Intravenous ascorbic acid as an adjuvant therapy for recombimetabolism parameters, and E-ZPP showed no significant nant erythropoietin in hemodialysis patients with hyperferritichanges in controls (N ϭ 15) and in non-responders (N ϭ 19).
Intravenous ascorbic acid as an adjuvant therapy for recombimetabolism parameters, and E-ZPP showed no significant nant erythropoietin in hemodialysis patients with hyperferritichanges in controls (N ϭ 15) and in non-responders (N ϭ 19).
nemia.
Thirty-seven patients (18 responders and 19 non-responders) Background. Inadequate iron mobilization and defective were further analyzed by receiver operating characteristic iron utilization may cause recombinant erythropoietin (rEPO) curves to seek the criteria for prediction of a response to IVAA hyporesponsiveness in hemodialysis (HD) patients with iron treatment. The results showed that E-ZPP at a cut-off level of overload. We have demonstrated that intravenous ascorbic acid more than 105 mol/mol heme and TS at a level of less than (IVAA), but not intravenous iron medication, can effectively 25% were more specific to confirm the status of functional iron circumvent the functional iron-deficient erythropoiesis assocideficiency in iron-overloaded patients. The two criterion values ated with iron overload in HD patients. However, it is uncertain whether all HD patients with hyperferritinemia will consishad the highest accuracy to predict a response to treatment. tently respond to IVAA and which index may indicate funcConclusions. Functional iron-deficient erythropoiesis plays tional iron deficiency in the special entity. Therefore, a prospeca role in rEPO-hyporesponsive anemia in HD patients with tive study was conducted to establish the guidelines for IVAA hyperferritinemia. IVAA may be an adjuvant therapy for rEPO adjuvant therapy. in these patients, and E-ZPP of more than 105 mol/mol heme Methods. Sixty-five HD patients with serum ferritin levels and TS of less than 25% should be used to guide the IVAA of more than 500 g/liter were recruited and divided into the treatment. control (N ϭ 19) and IVAA (N ϭ 46) groups. IVAA patients with a hematocrit (Hct) of less than 30% received 300 mg of ascorbic acid three times per week for eight weeks. Controls
In the era of recombinant erythropoietin (rEPO), hyhad a Hct of more than 30% and did not receive the adjuvant therapy. Red blood cell and reticulocyte counts, iron metaboperferritinemia in dialysis patients is always attributed lism indices, erythrocyte zinc protoporphyrin (E-ZPP), and the to previous multiple transfusions and overtreatment with concentrations of plasma ascorbate and oxalate were examined intravenous iron if the state of inflammation, liver disbefore and following the therapy.
ease, or malignancy is excluded. The ferritin level to
Results. Thirteen patients (four controls and nine IVAA indicate hyperferritinemia for hemodialysis (HD) papatients) withdrew by the end of the study. Eighteen patients had a dramatic response to IVAA with a significant increase tients is suggested to be over 500 to 1000 g/liter [1-4].
in their hemoglobin and reticulocyte index and a concomitant Cellular iron overload plays an important role in a num-24% reduction in rEPO dose after eight weeks. This paralleled ber of pathological states. It produces a variety of deletea significant rise in serum iron and transferrin saturation (TS) rious effects, including hemosiderosis [5, 6] , hepatic and and a fall in E-ZPP and serum ferritin (baselines vs. 8 weeks, cardiac dysfunction [7] , and cardiovascular and infecserum iron 68 Ϯ 37 vs. 124 Ϯ 64 g/dl, TS 27 Ϯ 10 vs. 48 Ϯ 19%, E-ZPP 123 Ϯ 44 vs. 70 Ϯ 13 mol/mol heme, and serum [11] [12] [13] . Supplementation of iron is rational for functional iron-deficient erythropoiesis in dialysis patients receiving rEPO treatment. However, the promising ef-METHODS fect of intravenous iron medication in patients with iron
Patients and study design overload was not observed in our previous study [14] or From 1 November 1997 to 30 April 1998, a prospective the one by Goch et al [15] . The results were also found study was conducted at the Veterans General Hospital in scorbutic animals [16] . Supplementation of iron did (Taipei, Taiwan) to recruit 65 HD patients (29 men and not improve the anemia, but increased the deposition of 36 women) with serum ferritin values of more than 500 hemosiderin in spleen, small intestine, and bone marrow.
g/liter. Hyperferritinemia was related to previous mulBecause tissue iron deposition is sufficient enough to tiple blood transfusions or overtreatment with intravecause organ damage, the risks related to iron overload do not justify intravenous iron therapy for patients with nous iron. Inclusion criteria were time on HD for six hyperferritinemia. Consequently, an adjuvant therapy to months or more, duration of rEPO treatment for six combat the functional iron deficiency related to iron months or more, and serum ferritin and hematocrit (Hct) overload is urgently needed.
values that were stable for three consecutive months. In Bothwell et al reported that Bantu subjects with scurvy the preceding three months, none of the patients had had excessive iron deposits in tissues, which modified the received iron supplements or blood transfusions. Pametabolism of ascorbic acid [17] . It is still controversial tients were excluded if any of the following events ocas to whether normal plasma ascorbate values reflect a curred during the study: bleeding, blood transfusions, normal vitamin C status in uremics. Tissue concentration hemolysis, acute liver diseases, and infections. Most paof vitamin C is often decreased in patients with iron tients routinely received multivitamin supplementation, overload, perhaps because of increased vitamin oxidabut the supplements did not include vitamin C in our tion catalyzed by iron. Moreover, subclinical vitamin C center. In the dietary survey data for estimating nutrient deficiency is frequently encountered in HD patients owintake [30] , vitamin C content of the diet varied between ing to its removal during dialysis and insufficient dietary 40 and 302 mg/day before the start of the investigation. intake [18] [19] [20] . Thus, systemic supplementation of ascorPatients were dialyzed for 4.0 to 4.5 hours three times bic acid is recommended. Gastaldello et al [21] and Tarng and Huang [14] had demonstrated that intravenous per week using cellulose acetate hollow-fiber (FB 130T, ascorbic acid (IVAA) treatment effectively improves the Nipro; Nissho, Japan), blood flow of 275 to 300 ml/min, resistant anemia associated with functional iron defiand dialysate flow of 500 ml/min. The study was approved ciency in HD patients with iron overload. A number by the local medical ethics committee, and informed of investigations suggested that ascorbic acid might be consent was obtained from each of the patients. involved in several phases of iron transport [16, 17, 22, Patients were stratified into IVAA and control groups 23]. Ascorbic acid, a reducing agent, is able to release according to Hct values. Basal Hct values were less than iron from ferritin and mobilize iron from the reticuloen-30% in IVAA group and were more than 30% in condothelial system to transferrin [14, 21] . This leads to an trols. IVAA patients received ascorbic acid, 300 mg each, increase of iron availability. administered intravenously for three minutes postdialHowever, the role of ascorbic acid in the enzymatic ysis three times per week. The study period included incorporation of iron into protoporphyrin for heme syneight weeks of treatment and four weeks of post-treatthesis [22, 23] has never been studied in this field. Zinc ment follow-up. Based on the study by Gastaldello et protoporphyrin (ZPP) is a by-product of heme biosynal, erythropoiesis was not further enhanced by IVAA thesis. Erythrocyte ZPP (E-ZPP) levels will increase if treatment in patients with good response to rEPO [21] . the enzymatic iron incorporation for heme synthesis is insufficient or suppressed. Accordingly, an increased Thus, controls did not receive the adjuvant therapy in our E-ZPP value indicates functional iron deficiency [24] [25] [26] [27] .
study. rEPO (Eprex; Cilag, Schaffhausen, Switzerland) In this study, we therefore applied the conventional iron was administered subcutaneously twice or three times metabolism indices and E-ZPP to elucidate the mechaper week, and the dose was maintained during the initial nism of action of IVAA. On the other hand, it is uncertwo weeks. After two weeks, the dose was decreased by tain whether all patients with hyperferritinemia and a 3 ϫ 15 U/kg/week if the Hct increased to more than suboptimal response to rEPO will respond to the IVAA 31%. The dose was titrated biweekly to maintain a target treatment. For the sake of cost-effectiveness, we anaHct value of 30 to 31%. Response to IVAA treatment lyzed the markers to set up the criteria for functional was defined as an increase in Hct of 3% or more or a iron deficiency in patients with hyperferritinemia and decreased in rEPO dose of more than 25% over the to guide the IVAA as an adjuvant therapy for rEPO.
baseline value at study completion. In subjects who failed Secondary oxalosis is a potential risk in HD patients to show a positive response to IVAA for four weeks, treated with excessive ascorbic acid [28, 29] . It is mandarEPO dose was further increased by 3 ϫ 15 U/kg/week tory to monitor the plasma oxalate concentration to avoid the inadvertent side effect during the IVAA treatment.
biweekly if Hct declined.
Laboratory measurements
0.5 ml of MPA-treated plasma. After thoroughly and slowly mixing, the mixture was allowed to stand for 30 Blood was drawn predialysis after an overnight fast. minutes at room temperature and then centrifuged for Hematocrit and hemoglobin (Hb) levels, and the reticu-15 minutes at 1000 ϫ g. The blue-colored supernatant locyte index were checked biweekly and were determined was transferred to another test tube, and absorbance at with a Coulter counter. Reticulocyte was measured by 700 nm was read against a blank constituted with distilled an automated flow cytometer, and a reticulocyte index water. For every set, a standard (1 mg/dl ascorbic acid was calculated using the following formula: observed with 0.5% oxalic acid) and a blank were run in parallel reticulocyte count (%) ϫ (patient's Hct Ϭ 45%). E-ZPP throughout the procedure. and iron metabolism indices including serum iron, total Plasma oxalate was measured by the method described iron-binding capacity (TIBC), and serum ferritin were by Petrarulo et al [33] . Briefly, 1 ml of 10-fold diluted measured before, as well as two, four, and eight weeks plasma was added with 100 l of 1.57 mol/liter sulfosalifollowing therapy. ZPP was determined by a fluorometer cylic acid solution for deproteinization. After centrifugadescribed by Schifman and Finley [31] . In brief, 2 ml tion for 10 minutes at 5000 ϫ g and 4ЊC, 700 l of the of blood in an ethylenediaminetetraacetic acid (EDTA) supernatant was mixed with 700 l of buffered charcoal tube was centrifuged for five minutes at 500 ϫ g within suspension (100 mg of charcoal in 10 ml of phosphate/ 10 minutes of collection. The supernatant was removed, EDTA buffer, pH 7.3). The 750 l of charcoal-treated and erythrocytes were washed twice with an equal volsample combined with 600 l of 25 mmol/liter 3-methylume of 0.9% saline. A microscope slide, on which 25 l 2-benzothiazolione hydrazone hydrochloride/8.2 mmol/ of washed erythrocytes were placed, was put into a hemaliter 3-dimethylaminobenzoic acid, and 150 l of 1000 tofluorometer (Aviv Biomedical Inc., Lakewood, NJ, U/ml peroxidase were incubated for 30 minutes at room USA) for the measurement of ZPP. Calibration with temperature. The mixture (700 l) was added with 140 l standard control was performed before testing. Serum of 3.3 U/ml oxalate oxidase and incubated for 60 minutes iron was measured by a colorimetric method (Hitachi at room temperature. Absorbance at 590 nm was read 736-60 autoanalyzer; Naka, Japan), TIBC by the TIBC with a spectrophotometer (Hitachi U-3300; Naka, JaMicrotest (Daiichi, Tokyo, Japan), and ferritin by a rapan). Blanks were prepared similarly by substituting wadioimmunoassay (Incstar, Stillwater, MN, USA). Transter for oxalate oxidase. ferrin saturation (TS) was equal to divide serum iron by TIBC ϫ 100.
Statistical analysis To investigate the factors pertaining to rEPO responStatistical analysis was performed using the computer siveness, serum aluminum, intact parathyroid hormone software Statistical Package of Social Science (SPSS 7.5, (PTH), inflammatory indices (C reactive protein and 1996; SPSS Inc., Chicago, IL, USA). Data were exfibrinogen), and hemolytic indices (haptoglobin and repressed as mean values Ϯ sd. Analysis of variance folticulocyte index) were checked at the inception of study.
lowed by pair-wise multiple comparison was used for Serum aluminum was determined in duplicate by a comparison of more than two groups. Pearson's chigraphite furnace atomic absorption spectrophotometer square test was used for frequency measures. A within-(GBC-906 spectrophotometer; Dandenong, Australia).
group comparison among post-treatment values and The detection limit was 0.5 g/liter, and the coefficient baselines was analyzed by analysis of variance for reof variation was lower than 4%. Serum intact PTH was peated measures, followed by pair-wise multiple comparmeasured by a radioimmunoassay (Incstar), C reactive ison. Receiver operating characteristic analysis was perprotein by a rate nephrelometry (Beckman, Galway, Ireformed to calculate the cut-off values, sensitivity, land), fibrinogen by the clotting method (Diagnostics specificity, and positive and negative predictive values. Stago, Asnieres-Sur-Seine, France), and haptoglobin by A P value of less than 0.05 was considered statistically radial immunodiffusion (Behring Diagnostics, Marburg, significant. Germany).
The concentrations of plasma ascorbate and oxalate RESULTS were determined in duplicate before, as well as four and eight weeks into the study. Plasma ascorbate was Thirteen patients (4 in controls and 9 in the IVAA measured by a method described by Kyaw [32] . An aligroup) had withdrawn by the end of study because of quot of 0.5 ml plasma was mixed with 0.5 ml of 100 g/ gastrointestinal bleeding (N ϭ 5), pneumonia (N ϭ 2), liter metaphosphoric acid (MPA) and stored at Ϫ70ЊC uremic pericarditis (N ϭ 1), cervical carcinoma (N ϭ 1), until measurement. Color reagent was prepared by mixand discontinuation of therapy (N ϭ 4). Finally, a total ing 0.3 mmol/liter sodium tungstate, 1.2 mmol/liter soof 52 patients completed the study: 15 in controls, 18 in dium hydrogen phosphate, and 18 mol/liter sulfuric acid.
the IVAA responders, and 19 in the non-responders (Table 1 ). The three groups were similar with regard to One milliliter of color reagent was slowly added into age, sex, duration of HD, time on rEPO treatment, and U/kg/week) and at eight weeks (75 Ϯ 44 U/kg/week) were significantly reduced as compared with baseline causes of chronic renal failure. Hb and Hct values were significantly lower, and the rEPO dose was markedly values (P Ͻ 0.05) in responders. On the contrary, the rEPO dose of non-responders modestly increased from higher in both IVAA responders and non-responders as compared to controls. Serum ferritin, serum iron, and 100 Ϯ 20 to 123 Ϯ 69 U/kg/week at treatment completion, and it became significantly higher than that in responders other factors pertaining to rEPO responsiveness showed no differences among the three groups. None of the at eight weeks (Fig. 1B) . The overall rEPO dose had a 24% reduction in responders and a 23% increment in patients in the treatment groups received any active vitamin D analogue. Impressively, TS was significantly non-responders. Sixty-seven percent of responders could reduce rEPO dose at treatment completion, whereas lower, and E-ZPP was significantly higher in IVAA responders than those in the others.
29% of non-responders needed to increase rEPO dose. In control subjects, the rEPO dose remained stable for Effect of intravenous ascorbic acid therapy eight weeks. Mean values of Hb (10.8 Ϯ 0.8 g/dl at baseline vs. 10.4 Ϯ 1.0 g/dl at 8 weeks), Hct (31.5 Ϯ 2.1% Hemoglobin and Hct values significantly increased at two weeks and all subsequent weeks following ascorbate vs. 31.1 Ϯ 2.4%), and reticulocyte index (1.2 Ϯ 0.3% vs. 1.4 Ϯ 0.3%) in controls kept steady throughout the study treatment in the IVAA responders (Fig. 1A) . Mean Hb, Hct, and reticulocyte index increased from 8.8 Ϯ 0.5 g/dl (Fig. 1) . at baseline to 10.7 Ϯ 0.9 g/dl at eight weeks (P Ͻ 0.001) Post-treatment follow-up and monitoring plasma from 26.4 Ϯ 1.8 to 31.6 Ϯ 2.8% (P Ͻ 0.001) and from ascorbate and oxalate 1.4 Ϯ 0.6 to 2.9 Ϯ 0.8% (P Ͻ 0.05), respectively. Nonresponders, however, showed no improvement in mean Hemoglobin values significantly decreased from 10.7 Ϯ 0.9 to 9.9 Ϯ 0.7 g/dl (Fig. 2) , and the rEPO dose increased values of Hb (8.5 Ϯ 0.8 g/dl at baseline vs. 8.2 Ϯ 1.0 g/dl at 8 weeks), Hct (25.0 Ϯ 2.6 vs. 24.0 Ϯ 3.0%), and from 75 Ϯ 44 to 94 Ϯ 47 U/kg/week in responders four weeks after stopping IVAA treatment. However, there reticulocyte index (1.9 Ϯ 0.5 vs. 2.1 Ϯ 0.8%).
Therapeutic doses of rEPO at four weeks (84 Ϯ 34 were no significant changes of Hb values (8.2 Ϯ 1.0 g/dl compared with baseline values. Serum iron markedly increased at two weeks and all subsequent weeks, and this paralleled a significant increase in TS (Fig. 3) . The four parameters in non-responders and controls had no significant changes during the treatment period. At treatment completion, serum ferritin became significantly lower and serum iron higher in responders as compared with non-responders. TS and E-ZPP of the patients in the three groups were similar at eight weeks.
Indices to predict who will respond to the intravenous ascorbic acid treatment
To identify the indices to predict a response to the IVAA treatment, 18 responders plus 19 non-responders were further analyzed by receiver operating characteristic curves ( Table 3 ). The results showed that E-ZPP and TS were more specific to all the tests at the cut-off values of more than 105 mol/mol heme and less than 25%, respectively (Fig. 4) . The criterion values indicated the status of functional iron deficiency with the highest accuracy (minimal false negative and false positive results) in iron-overloaded patients. The positive predictive value increased from 86 to 87 to 100%, and the negative predictive value was 70% when the two markers at the corresponding cut-off values were combined to use.
DISCUSSION
A deficiency of water-soluble vitamin C has been reported in HD patients owing to inadequate dietary in- of ascorbic acid is essential. A daily dose of 100 to 200 mg is recommended in some reports [18] [19] [20] 34 ], but the prescription of vitamin C in different dialysis facilities varies between 55 and 1000 mg daily [34] [35] [36] . Excessive at 8 weeks vs. 7.9 Ϯ 0.7 g/dl at 12 weeks) and rEPO dose vitamin C treatment may worsen uremic-related ox-(123 Ϯ 69 vs. 121 Ϯ 65 U/kg/week) in non-responders.
alosis. Hence, supplementation not exceeding 150 mg/ The body weight (controls, responders, and non-respondday (1050 mg weekly) is still considered a safe dose [29] . ers at 52 Ϯ 9, 57 Ϯ 16, 54 Ϯ 10 kg, respectively) and
In this study, the dose of IVAA (900 mg weekly) is less vitamin C content of daily diet (controls, responders, than the recommended regimen. Following a short-term and non-responders at 140 Ϯ 92, 146 Ϯ 83, and 136 Ϯ treatment, plasma oxalate concentrations only modestly 89 mg/day, respectively) were comparable among the increased as compared with baselines (P Ͼ 0.05). three groups. The concentrations of basal plasma ascorAscorbic acid was administered intravenously in this bate and plasma oxalate were also similar in the three study. It has the advantage of the oral route. The biogroups (Table 2) . Following eight weeks of treatment, availability is variable in HD patients receiving oral the concentrations of plasma ascorbate significantly inascorbic acid. Furthermore, gastrointestinal upset (especreased in both responders and non-responders (P Ͻ cially at a large dose) and noncompliance may reduce 0.01), but plasma oxalate modestly increased over basethe efficacy of oral treatment. lines without reaching statistical significance (P Ͼ 0.05).
The three groups of patients in our study were equivaAlterations in iron metabolism indices and erythrocyte lent with respect to the basal concentrations of plasma zinc protoporphyrin ascorbate. However, it is unclear whether normal plasma values reflect a normal vitamin C status. The metabolism In the IVAA responders, the mean values of serum ferritin and E-ZPP at eight weeks significantly decreased of ascorbic acid and iron is believed to be interrelated. and potentiates the enzymatic iron incorporation into as a result of irreversible oxidation of ascorbate by the protoporphyrin [23] . ZPP is a by-product of heme synexcessive deposits of ferric iron [37] . Anemia improved thesis. Its level in the erythrocyte may increase if the after the administration of IVAA and relapsed after enzymatic incorporation of iron into protoporphyrin is stopping treatment in the 18 responders. It might be suppressed or insufficient. Thus, E-ZPP was recently repossible that tissue ascorbate depleted severely in the ported as a marker of endogenous iron-deficient erythroiron-overloaded responders. Although there is no conpoiesis in renal as well as nonrenal anemia [24] [25] [26] [27] . In crete evidence to support this contention, two observathis study, basal E-ZPP levels in responders substantially tions are at least compatible with it [14, 21] .
elevated as compared with the other two groups and In the scorbutic animals [16] and the Bantu with scurvy significantly decreased after eight weeks of the IVAA [17] , defective iron utilization related to ascorbate defitreatment. Our results corroborate the observations [22-ciency was indicated by several observations, including 27]. The dual effects of IVAA treatment, an increase of normocytic and normochromic anemia, diminished iron mobilization, and an improvement of heme biosynplasma iron, and increased free erythrocyte protoporthesis enhance the erythropoietic response to rEPO and result in a Hb rise. phyrin. TS is one of the markers for iron availability No elevation of Hb was noted in non-responders after months or more. Gastaldello et al reported that there was no significant change in Hct or TS in seven control challenge with IVAA. The non-responders significantly had higher basal TS and lower E-ZPP as compared with patients without resistance to rEPO following IVAA treatment [21] . Accordingly, we believe that it is illogical responders. It implied that the iron availability and utilization are sufficient in this group. Because individual to administer IVAA medication to all our patients. The use of IVAA can be considered as an adjuvant therapy response to rEPO is variable in dialysis or predialysis patients [38, 39] , the increase of rEPO dose by an escalafor rEPO if hyporesponsive anemia related to functional iron deficiency occurred in HD patients with hyperferritition manner should be considered while other factors pertaining to rEPO resistance (Table 1) do not exist.
nemia. With the consideration of cost-effectiveness, we further analyzed the basal iron metabolism indices and Controls in this study had an optimal response to rEPO and maintained the stable erythropoiesis for three E-ZPP to establish the therapeutic guidelines for the nous iron for six months [46] . On the contrary, a high E-ZPP level (more than 105 mol/mol heme) not only represents a marker of endogenous iron availability but also a predictor for a response to IVAA in our study. In this study, anemia was improved after the administration of IVAA, and serum ferritin declined simultaneously at the end of the study. IVAA may also reduce the magnitude of iron overload in uremic patients. Confronted with the potential hazards of iron overload, IVAA provides an additional benefit for iron-overloaded HD patients because of its property mimicking iron-chelation agents. Ascorbic acid combined with desferrioxamine (DFO) results in very efficient removal of iron in nonuremic patients with iron overload [47, 48] . It has been demonstrated that DFO enhances burstforming unit-erythroid proliferation [49] and also im- proves anemia in iron-overload HD patients [15, 50] . overload. Certain laboratory and clinical observations have raised concern about the safety of using ascorbic acid in patients with severe iron overload. Some cardiac deaths [47, 48] and deterioration of cardiac function [51] IVAA treatment. Receiver operating characteristic curves were used to calculate the cut-off value of each have been reported in thalassemic children receiving index that could maximize the sensitivity, specificity, and DFO and ascorbic acid. Ascorbic acid promotes electron predictive values. We found that E-ZPP at a cut-off value exchange and, in vitro, can be shown to enhance the of more than 105 mol/mol heme and TS of less than cytotoxicity of iron. However, similar findings were not 25% were more specific to the status of functional ironobserved in nonthalassemic adults with transfusional deficient erythropoiesis in patients with iron overload.
iron overload during chelation therapy [52] , and vitamin E-ZPP and TS at the cut-off values had the superior C exhibits antioxidant activity in iron-overloaded human positive predict values for predicting a response to IVAA plasma [53] . Despite that untoward cardiac events associtreatment. If both tests were abnormal, the positive preated with ascorbic acid may not be a potential problem dictive value increased to 100%. in uremic patients, it is mandatory to evaluate and follow Transferrin saturation indicates a balance between up the cardiac function, particularly when vitamin C is supply and demand of plasma iron. TS has wide fluctuabeing administered intravenously on a weekly basis [51, tions because of a diurnal variation in serum iron and 52]. Because many patients with iron overload have retransferrin affected by the nutritional status. Nevertheceived the drug without any apparent harm, data from less, a series of follow-up is crucial if TS is to act as an large-scale, prospective, and controlled trials are needed index of functional iron deficiency [40] . A TS of less than to determine the safety and efficacy of a long-term IVAA 16 to 20% is suggestive of functional iron deficiency in HD patients with iron overload. [41-43]. However, it may lead to underdiagnosis in most HD patients when current guidelines for TS are used. ACKNOWLEDGMENTS The diagnostic threshold was raised to the level of 25% This study was supported by grants from the National Science Coun- [12, 13] results may be related to different selection of the study population. Furthermore, Braun et al proposed that REFERENCES E-ZPP cannot be used to predict the erythropoietic response to iron supplementation owing to no significant decrease of E-ZPP in HD patients treated with intrave-
